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A B S T R A C T
Chloasma is a required hypermelanosis of sun-exposed areas occurred during pregnancy and it can affect 50–70% of
pregnant women. It presents as symmetric hyperpigmented macules, which can confluent or punctuate. The most com-
mon locations are the cheeks, the upper lip, the chin and the forehead. The exact mechanism by which pregnancy affects
the process of melanogenesis is unknown. Estrogen, progesterone, and melanocyte-stimulating hormone (MSH) levels
are normally increased during the third trimester of pregnancy. However, nulliparous patients with chloasma have no
increased levels of estrogen or MSH. In addition, the occurrence of melasma with estrogen- and progesterone-containing
oral contraceptive pills has been reported. The observation that postmenopausal woman who are given progesterone de-
velop melasma, while those who are given only estrogen do not, implicates progesterone as playing a critical role in the
development of melasma. UV-B, UV-A, and visible light are all capable of stimulating melanogenesis. The condition is
self-limited; however spontaneous resolution is time-consuming and may take months to resolve normal pigmentation.
Therefore, it is worthwhile to prevent the onset of chloasma, by strict photoprotection. Prudent measures to avoid sun ex-
posure include hats and other forms of shade combined with the application of a broad-spectrum sunscreen at least daily.
Sunscreens containing physical blockers, such as titanium dioxide and zinc oxide, are preferred over chemical blockers
because of their broader protection. Chloasma can be difficult to treat. Quick fixes with destructive modalities (eg, cryo-
therapy, medium-depth chemical peels, lasers) yield unpredictable results and are associated with a number of potential
adverse effects. The mainstay of treatment remains topical depigmenting agents. Hydroquinone (HQ) is most commonly
used.
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Chloasma is a required hypermelanosis of sun-ex-
posed areas and it can affect 50–70% of pregnant women.
It presents as symmetric hyperpigmented macules, which
can confluent or punctuate. The most common locations
are the cheeks, the upper lip, the chin and the forehead1.
Chloasma is a synonymous term sometimes used to de-
scribe the occurrence of melasma during pregnancy. Chlo-
asma is derived from the Greek word chloazein,meaning
»to be green.« Melas, also Greek, means »black.« Since
the pigmentation is never green in appearance, melasma
is the preferred term2.
Chloasma is more common in women than in men,
and women are affected in 90% of cases. It can affect
50–70% of pregnant women. Melasma is rare before pu-
berty. Persons of any race can be affected. However, it is
much more common in constitutionally darker skin ty-
pes than in lighter skin types. More than 30% of patients
have a family history of melasma. Identical twins have
been reported to develop melasma3 while other siblings
under similar conditions did not.
The pathophysiology of melasma is uncertain. The
most important factor in the development of melasma is
exposure to sunlight. Ultraviolet radiation can cause
peroxidation of lipids in cellular membranes, leading to
generation of free radicals, which could stimulate mela-
nocytes to produce excess melanin. Sunscreens that pri-
marily block UV-B radiation (290–320 nm) are unsatis-
factory because longer wavelengths (UV-A and visible
radiation, 320–700 nm) also stimulate melanocytes to
produce melanin. In many cases there is a direct relation-
ship between melasma and female hormonal activity4 be-
cause melasma most often occurs in pregnancy and while
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using contraceptive pills5. Hormonal influences play a
role in some individuals. The mask of pregnancy is well
known to obstetric patients. The exact mechanism by
which pregnancy affects melasma is unknown. Estrogen,
progesterone, and melanocyte-stimulating hormone
(MSH) levels are normally increased during the third tri-
mester of pregnancy. The other factors that also contrib-
ute are photosensitizing medications, mild ovarian or
thyroid dysfunction, and certain cosmetics. The clinical
picture of melasma is tan to brown macular hiperpig-
mentation. Sometimes blue or black pigmentation can
develop in patients with dermal melasma. The depth of
the pigment can be visualized by use of a Wood lamp
(wavelength, 340–400 nm). Epidermal pigment is en-
hanced during examination with a Wood light, whereas,
dermal pigment is not. In individuals with dark-brown
skin, examination with a Wood light does not localize pig-
ment, and these patients are thus classified as indetermi-
nate. There are three types of distribution: centrofacial,
malar, or mandibular1.
Recent studies showed that melasma was related with
significant reduction in quality of life. Results of the in-
terviewed women showed that 65% of women were both-
ered all the time or most of the time, was frustrated
(55%), embarrassed (57%). Furthermore, they reported
significant influence of the disease on interpersonal rela-
tionships6. After the treatment, the number of women
who still reported disturbances reduced significantly. The
differential diagnosis includes Addison Disease, drug-In-
duced Photosensitivity, discoid Lupus Erythematosus,
mastocytosis, poikiloderma of Civatte 1. The clinical pic-
ture of melasma is typical and usually the no laboratory
tests are indicated. If thyroid dysfunction is the potential
causative agent, one can check thyroid function test.
Wood light examination usually helps to localize the pig-
ment to the epidermis or the dermis. Note that in many
cases, the pigment is found in both locations. Melanin is
increased in the epidermis, in the dermis, or (most com-
monly) in both locations. Epidermal melanin is found in
keratinocytes in the basal and suprabasal area. In most
cases, the number of melanocytes is not increased, yet
the melanocytes that are present are larger, more den-
dritic, and more active. Dermal melanin is found in the
superficial and mid dermis within macrophages, which
often congregate around small, dilated vessels. Inflam-
mation is sparse or absent2.
Melasma can be difficult to treat. The pigment of
melasma develops gradually, and resolution is also grad-
ual. Resistant cases or recurrences occur often and are
certain if strict avoidance of sunlight is not rigidly heeded.
All wavelengths of sunlight, including the visible spec-
trum, are capable of inducing melasma. Quick fixes with
destructive modalities (eg. cryotherapy, medium-depth
chemical peels, lasers) yield unpredictable results and
are associated with a number of potential adverse effects,
including epidermal necrosis, post inflammatory hyper-
pigmentation, and hypertrophic scars7,8. The precise ma-
nner in which these modalities can be used has not been
fully delineated. However, in some experienced hands,
they have been anecdotally reported to be safe, effective,
and produce results much quicker than topical medi-
cations9. More careful study is needed before they can be
recommended as a standard treatment. In an attempt to
hasten resolution, many practitioners attempt mild exfo-
liation with superficial chemical peels10. The rational is
that if melanogenesis is inhibited with bleaching agents
and keratinocyte turnover is increased, the time to reso-
lution can be reduced. A number of studies have shown
that treating melasma with superficial chemical peels
and a bleaching agent is safe and effective. Whether su-
perficial chemical peels versus bleaching agents alone ac-
tually hasten the resolution of pigment is debated. Stu-
dies comparing bleaching agents alone to the combina-
tion of bleaching agents and superficial chemical peels
are ongoing and may help to resolve the debate. The
mainstay of treatment remains topical depigmenting
agents. Hydroquinone11 (HQ) is most commonly used12.
The mechanism of action is inhibition of tyrosinase, lead-
ing to the decreased production of melanin. HQ can be
applied in cream form or as an alcohol-based solution.
Concentrations vary from a 2% to 4 % concentration and
even higher when compounded. All concentrations can
lead to skin irritation, phototoxic reactions with second-
ary post inflammatory hyperpigmentation, and irrevers-
ible exogenous ochronosis. Another treatment option is
use of tretinoin13,14 (trans-retinoic-acid) but is less effec-
tive than HQ. However, the response to treatment is less
than with HQ and can be slow, with improvement taking
6 months or longer. As such, combinations of tretinoin
with HQ, with or without a topical corticosteroid15, have
been promoted. The retinoid is believed to work by in-
creasing keratinocyte turnover and thus limiting the
transfer of melanosomes to keratinocytes. The major ad-
verse effect is skin irritation, especially when the more
effective, higher concentrations are used. Temporary
photosensitivity and paradoxical hyperpigmentation can
also occur. The mechanism of action by which azelaic
acid16 act is not certain, but it seems that azelaic acid tar-
gets only hyperactive melanocytes and thus will not
lighten skin with normally functioning melanocytes. The
primary adverse effect is skin irritation.
Regardless of the treatments used, all will fail if sun-
light is not strictly avoided. Prudent measures to avoid
sun exposure include hats and other forms of shade com-
bined with the application of a broad-spectrum sun-
screen at least daily. Sunscreens containing physical blo-
ckers, such as titanium dioxide and zinc oxide, are pre-
ferred over chemical blockers because of their broader
protection17,18.
All of this therapy reduces epidermal pigment. Der-
mal pigment may take longer to resolve than epidermal
pigment because no effective therapy is capable of re-
moving dermal pigment. However, treatment should not
be withheld simply because of a preponderance of dermal
pigment. The source of the dermal pigment is the epider-
mis, and, if epidermal melanogenesis can be inhibited for
long periods, the dermal pigment will not replenish and
will slowly resolve.
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KLOAZMA – MASKA TRUDNO]E
S A @ E T A K
Kloazma je ste~ena hipermelanoza koja nastaje na fotoeksponiranim podru~jima tijekom trudno}e, a mo`e se javiti i
kod 50–70% trudnica. Prikazuje se u vidu simetri~nih hiperpigmentiranih makula koje mogu biti pojedina~ne ili kon-
fluiraju}e. Predilekcijska mjesta su obrazi, gornja usnica, brada i ~elo. To~an mehanizam nastaka ovog stanja nije pot-
puno jasan. Razine estrogena, progesterona i MSH su normalno povi{ene tijekom posljednjeg trimestra trudno}e. Ipak,
prvorotkinje s ovim poreme}ajem nemaju povi{ene vrijednosti estrogena i MSH. Pored toga, dokumentirani su i slu~a-
jevi pojave kloazme kod `ena koje su uzimale peroralne kontraceptive bazirane na estrogenima i gestagenima. Podatak
da postmenopauzalne `ene koje uzimaju samo gestagene mogu razviti kloazmu, za razliku od onih koje uzimaju samo
estrogene, govore u prilog va`nosti progesterona u patogenezi ovih promjena. UV-B, UV-A zrake, kao i sun~evo svjetlo
mogu stimulirati melanogenezu. Ko`ne promjene kod kloazme se povla~e same, ali je spontana rezolucija vrlo spora i
mo`e trajati mjesecima. Stoga je vrijedno striktnom fotoportekcijom poku{ati sprije~iti nastanak. Mjere fotoprotekcije
uklju~uju {iroke {e{ire i druge oblike fizi~ke za{tite uz dodatnu primjenu fotoza{titnih krema. Kreme koje sadr`e fizi-
~ke zapreke kao titanov dioksid ili cinkov oksid su preporu~ljivije od kemijskih tipova za{tite. Jednom kada nastane,
lije~enje kloazme mo`e predstavljati terapijski izazov. Brzo lije~enje destruktivnim postupcima (krioterapija, kemijska
abrazija, laser) mo`e biti nepredvidivog ishoda i uz to povezano s mogu}im nuspojavama. Zlatni standard u terapiji su
lokalna depigmentiraju}a sredstva, od kojih je naj~e{}e kori{ten hidrokinon.
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